Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027430 · ClinicalTrials.gov registry record · NA
Androgen Replacement Therapy in Women With Hypopituitarism
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT00027430: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00027430 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027430, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a study to determine whether testosterone replacement with TheraDerm can improve bone density, mood, sex drive, thinking, and distribution of body fat and muscle mass in women with hypopituitarism.
Interventions
- DRUG TheraDerm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2001-09 |
| Est. Completion | 2004-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027430
The ClinicalTrials.gov registry entry for NCT00027430 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraDerm is the first listed.
NCT00027430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027430 about?
NCT00027430 is a clinical study titled "Androgen Replacement Therapy in Women With Hypopituitarism". This is a study to determine whether testosterone replacement with TheraDerm can improve bone density, mood, sex drive, thinking, and distribution of body fat and muscle mass in women with hypopituitarism.
What is the current status of trial NCT00027430?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2001-09. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00027430?
The interventions under investigation include: TheraDerm (DRUG).
Who is sponsoring clinical trial NCT00027430?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.